Literature DB >> 15066610

Use of the case-crossover design to study prolonged drug exposures and insidious outcomes.

Philip S Wang1, Sebastian Schneeweiss, Robert J Glynn, Helen Mogun, Jerry Avorn.   

Abstract

PURPOSE: The case-crossover design was originally intended to study brief exposures with immediate and transient effects, and acute outcomes with abrupt onsets. We investigated whether case-crossover methods can be used to study prolonged exposures and insidious outcomes.
METHODS: We conducted a case-crossover study of 8220 patients aged > or = 65 years enrolled in several health benefits programs in New Jersey during the period between 1991 and 1995. All had episodes of central nervous system (CNS) adverse events (e.g., delirium). Drug exposures were assessed during case time periods and control time periods lasting 1, 2, 3, or 4 months. Exposures included 3 active regimens with established deleterious CNS effects (corticosteroids, digoxin, and opiates) and 2 inactive regimens without such effects (multivitamins and statins).
RESULTS: In conditional logistic regression models, significantly elevated risks were observed for all three active drugs, regardless of which time windows were used. The magnitude of these risks generally increased with longer time windows. No significantly increased risks were observed for the 2 inactive drugs, regardless of the window duration.
CONCLUSIONS: These results suggest that with lengthened exposure assessment windows, case-crossover methods may be useful for studying exposures with prolonged effects and outcomes with insidious onsets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066610     DOI: 10.1016/j.annepidem.2003.09.012

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  9 in total

Review 1.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

2.  Health outcomes associated with potentially inappropriate medication use in older adults.

Authors:  Donna M Fick; Lorraine C Mion; Mark H Beers; Jennifer L Waller
Journal:  Res Nurs Health       Date:  2008-02       Impact factor: 2.228

3.  Evaluation of the Case-Crossover (CCO) Study Design for Adverse Drug Event Detection.

Authors:  Zachary Burningham; Tao He; Chia-Chen Teng; Xi Zhou; Jonathan Nebeker; Brian C Sauer
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

4.  Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients.

Authors:  Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-19       Impact factor: 8.237

5.  Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women.

Authors:  David B Hanna; Nancy A Hessol; Elizabeth T Golub; Jennifer M Cocohoba; Mardge H Cohen; Alexandra M Levine; Tracey E Wilson; Mary Young; Kathryn Anastos; Robert C Kaplan
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

Review 6.  Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review.

Authors:  Nathalie Gault; Johann Castañeda-Sanabria; Yann De Rycke; Sylvie Guillo; Stéphanie Foulon; Florence Tubach
Journal:  BMC Med Res Methodol       Date:  2017-02-08       Impact factor: 4.615

7.  Assessing short-term risk of ischemic stroke in relation to all prescribed medications.

Authors:  Imre Janszky; Ioannis Vardaxis; Bo Henry Lindqvist; Jens Wilhelm Horn; Ben Michael Brumpton; Linn Beate Strand; Inger Johanne Bakken; Ingvild Vatten Alsnes; Pål Richard Romundstad; Rickard Ljung; Kenneth Jay Mukamal; Abhijit Sen
Journal:  Sci Rep       Date:  2021-11-04       Impact factor: 4.379

8.  Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.

Authors:  Chia-Lin Liu; Wen-Yi Shau; Chia-Hsuin Chang; Chi-Shin Wu; Mei-Shu Lai
Journal:  J Epidemiol       Date:  2013-08-03       Impact factor: 3.211

9.  Medication use and the risk of motor vehicle collision in West Virginia drivers 65 years of age and older: a case-crossover study.

Authors:  Toni M Rudisill; Motao Zhu; Danielle Davidov; D Leann Long; Usha Sambamoorthi; Marie Abate; Vincent Delagarza
Journal:  BMC Res Notes       Date:  2016-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.